Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)-Reference-Cited by-同舟云学术

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

Published:2013-04 Issue:4 Volume:14 Page:306-316
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Langley Ruth E,Cafferty Fay H,Alhasso Abdulla A,Rosen Stuart D,Sundaram Subramanian Kanaga,Freeman Suzanne C,Pollock Philip,Jinks Rachel C,Godsland Ian F,Kockelbergh Roger,Clarke Noel W,Kynaston Howard G,Parmar Mahesh KB,Abel Paul D

Funder

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology

Reference38 articles.

1. Reimbursement policy and androgen-deprivation therapy for prostate cancer;Shahinian;N Engl J Med,2010

2. Contemporary role of androgen deprivation therapy for prostate cancer;Pagliarulo;Eur Urol,2012

3. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer;Freedland;Prostate Cancer Prostatic Dis,2009

4. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma;Lee;Cancer,2005

5. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer;Wadhwa;BJU Int,2010

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A primer of quasi-exact tests for randomized clinical trials with binary endpoints;Statistics in Biopharmaceutical Research;2024-09-10

2. The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens;Biomedicines;2024-07-23

3. A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design;Clinical Oncology;2024-01

4. Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS);Clinical Genitourinary Cancer;2023-10

5. Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil;American Journal of Physiology-Regulatory, Integrative and Comparative Physiology;2023-04-01